surmount-1 tirzepatide non-diabetic obesity weight loss For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Read now: The SURPASS-EARLY trial

Anyone starting or continuing a compounded GLP-1 program right now should understand the FDA's April 2026 proposal, ask their telehealth platform about pharmacy structure, and have a conversation with their clinician about contingency planning for their care if compounding availability changes

Discuss goal weight Explain that hitting a goal weight is not a cure and that long-term treatment of some sort may be necessary

At the moment, the use of such drugs is almost exclusively limited to people with a clear medical need to lose weight

If you are looking for energy support while staying consistent with your plan, Weight Loss Boost is another option to explore